Ensysce Biosciences Inc., a clinical-stage pharmaceutical company focused on developing innovative pain relief solutions, announced it has received a $5.3 million installment as part of a $15 million, three-year grant from the National Institute on Drug Abuse (NIDA). This funding will accelerate the development of PF614-MPAR, a next-generation opioid designed to reduce the risk of overdose while providing effective pain relief. This product has earned FDA Breakthrough Therapy designation, acknowledging its potential impact on pain management. The grant is solely awarded to Ensysce Biosciences, supporting the company's mission to deliver safer opioid alternatives and advance toward commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.